Transgenic Group (TSE:2342) Net Margin %: -1.54% (As of Mar. 2026)

What is Transgenic Group Net Margin %?

Transgenic Group TSE:2342 -0.96% 59 Net Margin % is -1.54% as of Mar. 2026. GuruFocus rates TSE:2342 with a GF Score™ of 59/100 and a GF Value™ of 円257.18 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Transgenic Group ranks better than 70.79% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Transgenic Group's Net Income for the six months ended in Mar. 2026 was 円-107 Mil. Transgenic Group's Revenue for the six months ended in Mar. 2026 was 円6,950 Mil. Therefore, Transgenic Group's net margin for the quarter that ended in Mar. 2026 was -1.54%.

The historical rank and industry rank for Transgenic Group's Net Margin % or its related term are showing as below:

TSE:2342' s Net Margin % Range Over the Past 10 Years
Min: -8.38 Med: 0.31 Max: 14.92
Current: -0.59

TSE:2342's Net Margin % is ranked better than
70.79% of 945 companies
in the Biotechnology industry
Industry Median: -89.33 vs TSE:2342: -0.59

Transgenic Group (TSE:2342) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Transgenic Group Net Margin % Related Terms

Transgenic Group Net Margin % Historical Data

* Premium members only.

The historical data trend for Transgenic Group's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgenic Group Net Margin % Chart

Transgenic Group Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Net Margin %

Get a 7-Day Free Trial

14.92

-3.58

0.03

-8.38

-0.59

Transgenic Group Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
Net Margin %	Get a 7-Day Free Trial															-0.66	-2.89	-13.56	0.47	-1.54

TSE:2342 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Transgenic Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgenic Group Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgenic Group's Net Margin % distribution charts can be found below:

* The bar in red indicates where Transgenic Group's Net Margin % falls into.

Save Embed

59GF Score

Transgenic Group Inc TSE:2342

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Transgenic Group Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Transgenic Group's Net Margin for the fiscal year that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (A: Mar. 2026 )	/	Revenue (A: Mar. 2026 )
	=	-77.267	/	13174.425
	=	-0.59 %

Transgenic Group's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-106.814	/	6949.572
	=	-1.54 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of -1.54% mean?

Transgenic Group (TSE:2342) has a Net Margin % of -1.54% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Transgenic Group and its competitors. According to the industry distribution chart, Transgenic Group ranks #276 out of 945 companies in the Biotechnology industry, placing it in the top 29.2%.

Is Transgenic Group's Net Margin % too high?

Transgenic Group's current Net Margin % is -1.54%. Based on the distribution chart, Transgenic Group ranks #276 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Transgenic Group has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Transgenic Group's Net Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Transgenic Group ranks #276 out of 945 companies for Net Margin %. This puts Transgenic Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Transgenic Group and its competitors. Transgenic Group's current Net Margin % is -1.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Transgenic Group stock overvalued right now?

Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円257.18, compared to a current price of 円207.00 — trading 19.5% below its estimated fair value. The current Net Margin % is -1.54%. Transgenic Group's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current Net Margin % is -1.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgenic Group (TSE:2342) Overvalued in 2026?

Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued. The current stock price of 円207.00 is trading 19.5% below its estimated GF Value™ of 円257.18. GuruFocus considers Transgenic Group to be Modestly Undervalued.

Key valuation signals for TSE:2342:

Net Margin %: -1.54%
GF Value™: 円257.18 vs. price of 円207.00 (19.5% below fair value)
GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgenic Group Business Description

Industry Healthcare Biotechnology

Comparable Companies TSE:4576 TSE:4591 TSE:2183 TSE:4884 TSE:177A TSE:206A TSE:130A TSE:4881 TSE:4893 TSE:4891 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 2-3-36 Tenjin, Chuo-ku, Fukuoka Prefecture, Fukuoka, JPN

Website https://www.transgenic.co.jp

Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.

59GF Score

Get the complete analysis for TSE:2342

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円207.00

Price

円257.18

GF Value

View TSE:2342 Analysis

See Net Margin % data for all stocks →